These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31610670)

  • 1. Lymphangioleiomyomatosis.
    Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
    Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
    Urban T; Lazor R; Lacronique J; Murris M; Labrune S; Valeyre D; Cordier JF
    Medicine (Baltimore); 1999 Sep; 78(5):321-37. PubMed ID: 10499073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus.
    Cabeza Osorio L; Ruiz Cobos MÁ; Casanova Espinosa Á
    Arch Bronconeumol; 2016 Jun; 52(6):329-30. PubMed ID: 25912780
    [No Abstract]   [Full Text] [Related]  

  • 7. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.
    Crausman RS; Lynch DA; Mortenson RL; King TE; Irvin CG; Hale VA; Newell JD
    Chest; 1996 Jan; 109(1):131-7. PubMed ID: 8549175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological alterations of lymphangioleiomyomatosis in 14 Chinese patients.
    Lu SH; Hou YY; Tan YS; Xu JF; Zeng HY; Sujie AK; Wang XD; Bai CX
    Chin Med J (Engl); 2009 Aug; 122(16):1895-900. PubMed ID: 19781367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
    Yates DH
    Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study.
    Sakurai T; Kanou T; Funaki S; Fukui E; Kimura T; Ose N; Inoue Y; Shintani Y
    Respir Investig; 2024 Jul; 62(4):657-662. PubMed ID: 38761480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
    Gao N; Zhang T; Ji J; Xu KF; Tian X
    Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
    Koba T; Arai T; Kitaichi M; Kasai T; Hirose M; Tachibana K; Sugimoto C; Akira M; Hayashi S; Inoue Y
    Respirology; 2018 Mar; 23(3):331-338. PubMed ID: 28960664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lymphangioleiomyomatosis].
    Wirtz H
    Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of lymphangioleiomyomatosis].
    Gao P; Huang R; Cai BQ; Liu HR
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):306-9. PubMed ID: 15266836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging clinical picture of lymphangioleiomyomatosis.
    Cohen MM; Pollock-BarZiv S; Johnson SR
    Thorax; 2005 Oct; 60(10):875-9. PubMed ID: 16055626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
    Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
    Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Steagall WK; Moss J
    Cancer Control; 2006 Oct; 13(4):276-85. PubMed ID: 17075565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.